50 related articles for article (PubMed ID: 15098798)
1. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Owor M; Tierney C; Ziemba L; Browning R; Moye J; Graham B; Reding C; Costello D; Norman J; Wiesner L; Hughes E; Whalen ME; Purdue L; Mmbaga BT; Kamthunzi P; Kawalazira R; Nathoo K; Bradford S; Coletti A; Aweeka F; Musoke P
Pediatr Infect Dis J; 2021 May; 40(5):446-452. PubMed ID: 33464021
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
Fillekes Q; Mulenga V; Kabamba D; Kankasa C; Thomason MJ; Cook A; Ferrier A; Chintu C; Walker AS; Gibb DM; Burger DM
AIDS; 2012 Sep; 26(14):1795-800. PubMed ID: 22739394
[TBL] [Abstract][Full Text] [Related]
4. Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
Dimala CA; Bechem NN; Aroke D; Kadia BM
BMC Res Notes; 2017 Nov; 10(1):623. PubMed ID: 29183354
[TBL] [Abstract][Full Text] [Related]
5. In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs.
Rojas Gómez R; Restrepo Valencia P
Colomb Med (Cali); 2015 Sep; 46(3):109-16. PubMed ID: 26600625
[TBL] [Abstract][Full Text] [Related]
6. Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection.
Kaul S; Kline MW; Church JA; Dunkle LM
Antimicrob Agents Chemother; 2001 Mar; 45(3):758-63. PubMed ID: 11181356
[TBL] [Abstract][Full Text] [Related]
7. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients.
Piscitelli SC; Kelly G; Walker RE; Kovacs J; Falloon J; Davey RT; Raje S; Masur H; Polis MA
Antimicrob Agents Chemother; 1999 Mar; 43(3):647-50. PubMed ID: 10049281
[TBL] [Abstract][Full Text] [Related]
8. Developmental pharmacokinetic changes of Lamivudine in infants and children.
Tremoulet AH; Nikanjam M; Cressey TR; Chokephaibulkit K; McKinney R; Mirochnick M; Capparelli EV
J Clin Pharmacol; 2012 Dec; 52(12):1824-32. PubMed ID: 22180560
[TBL] [Abstract][Full Text] [Related]
9. Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.
Sy SK; Malmberg R; Matsushima A; Asin-Prieto E; Rosenkranz B; Cotton MF; Derendorf H; Innes S
Int J Antimicrob Agents; 2015 Apr; 45(4):413-9. PubMed ID: 25697412
[TBL] [Abstract][Full Text] [Related]
10. Magnitude of adverse drug reaction and associated factors among HIV-infected adults on antiretroviral therapy in Hiwot Fana specialized university hospital, eastern Ethiopia.
Weldegebreal F; Mitiku H; Teklemariam Z
Pan Afr Med J; 2016; 24():255. PubMed ID: 27800108
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials.
Moore KH; Yuen GJ; Hussey EK; Pakes GE; Eron JJ; Bartlett JA
Antimicrob Agents Chemother; 1999 Dec; 43(12):3025-9. PubMed ID: 10582904
[TBL] [Abstract][Full Text] [Related]
12. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.
Kaul S; Christofalo B; Raymond RH; Stewart MB; Macleod CM
Antimicrob Agents Chemother; 1998 Sep; 42(9):2295-8. PubMed ID: 9736552
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
Asif G; Hurwitz SJ; Obikhod A; Delinsky D; Narayanasamy J; Chu CK; McClure HM; Schinazi RF
Antimicrob Agents Chemother; 2007 Jul; 51(7):2424-9. PubMed ID: 17485498
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the toxicity of different antiretroviral drugs and their combinations on Sertoli and Leydig cells.
Baysal M; Karaduman AB; Korkut Çelikateş B; Atlı-Eklioğlu Ö; Ilgın S
Drug Chem Toxicol; 2024 Apr; ():1-9. PubMed ID: 38647040
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.
Fauchet F; Treluyer JM; Frange P; Urien S; Foissac F; Bouazza N; Benaboud S; Blanche S; Hirt D
Antimicrob Agents Chemother; 2013 Oct; 57(10):4801-8. PubMed ID: 23877688
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.
Neely MN; Rakhmanina NY
Clin Pharmacokinet; 2011 Mar; 50(3):143-89. PubMed ID: 21294595
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.
Tremoulet AH; Capparelli EV; Patel P; Acosta EP; Luzuriaga K; Bryson Y; Wara D; Zorrilla C; Holland D; Mirochnick M;
Antimicrob Agents Chemother; 2007 Dec; 51(12):4297-302. PubMed ID: 17893155
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
Fletcher CV; Yogev R; Nachman SA; Wiznia A; Pelton S; McIntosh K; Stanley K
Pharmacotherapy; 2004 Apr; 24(4):453-9. PubMed ID: 15098798
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
